CN100418964C - (s,s)-顺式-2-二苯甲基-3-苄基氨基奎宁环的制备方法 - Google Patents

(s,s)-顺式-2-二苯甲基-3-苄基氨基奎宁环的制备方法 Download PDF

Info

Publication number
CN100418964C
CN100418964C CNB200380101563XA CN200380101563A CN100418964C CN 100418964 C CN100418964 C CN 100418964C CN B200380101563X A CNB200380101563X A CN B200380101563XA CN 200380101563 A CN200380101563 A CN 200380101563A CN 100418964 C CN100418964 C CN 100418964C
Authority
CN
China
Prior art keywords
acid
organic
salt
isomer
chiral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200380101563XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1705664A (zh
Inventor
T·C·努根特
R·希梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
DSM Pharmaceuticals Inc
Original Assignee
Pfizer Products Inc
DSM Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc, DSM Pharmaceuticals Inc filed Critical Pfizer Products Inc
Publication of CN1705664A publication Critical patent/CN1705664A/zh
Application granted granted Critical
Publication of CN100418964C publication Critical patent/CN100418964C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB200380101563XA 2002-10-16 2003-10-10 (s,s)-顺式-2-二苯甲基-3-苄基氨基奎宁环的制备方法 Expired - Fee Related CN100418964C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41905102P 2002-10-16 2002-10-16
US60/419,051 2002-10-16
PCT/US2003/032275 WO2004035575A1 (en) 2002-10-16 2003-10-10 Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine

Publications (2)

Publication Number Publication Date
CN1705664A CN1705664A (zh) 2005-12-07
CN100418964C true CN100418964C (zh) 2008-09-17

Family

ID=32108014

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200380101563XA Expired - Fee Related CN100418964C (zh) 2002-10-16 2003-10-10 (s,s)-顺式-2-二苯甲基-3-苄基氨基奎宁环的制备方法

Country Status (21)

Country Link
US (2) US6861526B2 (enExample)
EP (1) EP1551833A4 (enExample)
JP (1) JP2006506368A (enExample)
KR (1) KR100739901B1 (enExample)
CN (1) CN100418964C (enExample)
AP (1) AP2005003288A0 (enExample)
AR (1) AR041587A1 (enExample)
AU (1) AU2003277353B2 (enExample)
BR (1) BR0315335A (enExample)
CA (1) CA2500635A1 (enExample)
EA (1) EA008192B1 (enExample)
HR (1) HRP20050328A2 (enExample)
IS (1) IS7755A (enExample)
MX (1) MXPA05004058A (enExample)
PA (1) PA8586601A1 (enExample)
PE (1) PE20040777A1 (enExample)
PL (1) PL376218A1 (enExample)
TN (1) TNSN05111A1 (enExample)
UY (1) UY28024A1 (enExample)
WO (1) WO2004035575A1 (enExample)
ZA (1) ZA200502411B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
HUE034099T2 (en) * 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
DK1713801T3 (da) * 2004-02-02 2008-03-17 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法
CN108341811A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 马罗皮坦杂质的制备方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
WO2025172911A1 (en) * 2024-02-16 2025-08-21 Teadus Pharmaceuticals Pvt. Ltd A process for the preparation of (2s,3s)-2-benzhydryl- n-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine and pharmaceutically acceptable salts thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162339A (en) * 1988-11-23 1992-11-10 Pfizer Inc. Quinuclidine therapeutic agents
CN1067428A (zh) * 1991-05-31 1992-12-30 美国辉瑞有限公司 奎宁环衍生物
CN1068571A (zh) * 1991-05-22 1993-02-03 美国辉瑞有限公司 取代的3-氨基奎宁环
CN1091134A (zh) * 1992-11-12 1994-08-24 美国辉瑞有限公司 治疗炎症和胃肠疾病的奎宁环衍生物
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
US5138060A (en) 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
JP2909214B2 (ja) 1992-08-19 1999-06-23 フアイザー・インコーポレイテツド 置換ベンジルアミノ窒素含有非芳香族複素環化合物
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
MX9706944A (es) 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162339A (en) * 1988-11-23 1992-11-10 Pfizer Inc. Quinuclidine therapeutic agents
CN1068571A (zh) * 1991-05-22 1993-02-03 美国辉瑞有限公司 取代的3-氨基奎宁环
CN1067428A (zh) * 1991-05-31 1992-12-30 美国辉瑞有限公司 奎宁环衍生物
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
CN1091134A (zh) * 1992-11-12 1994-08-24 美国辉瑞有限公司 治疗炎症和胃肠疾病的奎宁环衍生物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
'Quinuclidine-based NK-1 antagonistsI:3-benzyloxy-1-azabicyclo?.2.2üoctanes'. SEWARD E.M. ET AL.BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS,Vol.3 No.6. 1993
'Quinuclidine-based NK-1 antagonistsI:3-benzyloxy-1-azabicyclo?.2.2üoctanes'. SEWARD E.M. ET AL.BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS,Vol.3 No.6. 1993 *

Also Published As

Publication number Publication date
JP2006506368A (ja) 2006-02-23
EP1551833A4 (en) 2010-06-02
US20050085641A1 (en) 2005-04-21
PA8586601A1 (es) 2005-02-04
MXPA05004058A (es) 2005-06-08
EP1551833A1 (en) 2005-07-13
US6861526B2 (en) 2005-03-01
CN1705664A (zh) 2005-12-07
UY28024A1 (es) 2004-05-31
TNSN05111A1 (en) 2007-05-14
HK1078087A1 (en) 2006-03-03
KR20050083764A (ko) 2005-08-26
WO2004035575A8 (en) 2005-05-12
EA008192B1 (ru) 2007-04-27
PL376218A1 (en) 2005-12-27
BR0315335A (pt) 2005-08-16
WO2004035575A1 (en) 2004-04-29
AR041587A1 (es) 2005-05-26
AP2005003288A0 (en) 2005-06-30
PE20040777A1 (es) 2004-11-20
EA200500650A1 (ru) 2005-10-27
CA2500635A1 (en) 2004-04-29
US20040116704A1 (en) 2004-06-17
IS7755A (is) 2005-03-17
ZA200502411B (en) 2006-05-31
HRP20050328A2 (en) 2005-06-30
AU2003277353A1 (en) 2004-05-04
KR100739901B1 (ko) 2007-07-13
AU2003277353B2 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
KR100739901B1 (ko) (ｓ,ｓ)-시스-2-벤즈하이드릴-3-벤질아미노퀴누클리딘의제조 방법
EP0763010B1 (en) Enantioselective preparation of optically pure albuterol
US8334385B2 (en) Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
JPH11505229A (ja) ４−アリール−ピペリジン誘導体を製造する方法
HU216629B (hu) Eljárás 1-aza-biciklo[2.2.2]okt-3-il származékok előállítására
JP2007519710A (ja) １−（２Ｓ，３Ｓ）−２−ベンズヒドリル−Ｎ−（５−ｔｅｒｔ−ブチル−２−メトキシベンジル）キヌクリジン−３−アミンの製造方法
WO2002006275A1 (en) Novel processes for the preparation of 4-phenylpiperidine derivatives
EP2132192B1 (en) Novel process for preparation of duloxetine hydrochloride
EP0773921B1 (en) Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
JP2546624B2 (ja) 光学的に純粋なアミノアルコールの製造方法
JPH0757747B2 (ja) フィソスチグミンの製造における中間体として使用されるアルキル化オキシインドールのエナンチオ選択的合成方法
JP2004520333A (ja) （±）−トランス−４−ｐ−フルオロフェニル−３−ヒドロキシメチル−１−メチルピペリジンの製造方法。
HK1078087B (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine
CN1989097A (zh) 用于制备非对映异构体富集的化合物的方法
JP2007515459A (ja) トルテロジンを得るための方法
JP2002540108A (ja) ［Ｓ−（Ｒ＊，Ｓ＊）］−β−［［［１−［１−オキソ−３−（４−ピペリジニル）プロピル］−３−ピペリジニル］カルボニル］アミノ］−３−ピリジンプロパン酸及び誘導体を製造する方法
US20100261775A1 (en) Polymorphic form of duloxetine hydrochloride
KR100915666B1 (ko) 광학적으로 순수한 (ｓ)-3-히드록시피롤리딘의 제조방법
CZ296345B6 (cs) Zpusob výroby hydrochloridu (R)-N-methyl-3-(2-methylfenoxy)-3-fenylpropylaminu (atomoxetinu)
CN100341850C (zh) 去甲基苯环壬酯光学异构体与n－对甲基苯磺酰谷氨酸光学异构体的盐及其制备方法和用途
WO2024223428A1 (en) Process for preparing 5-{2-[benzyl-(1-(4-hydroxyphenyl)-1-methylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol hemifumarate
JP2002128745A (ja) 光学活性１，２−ビス（２，４，６−トリメチルフェニル）−１，２−エタンジアミンの製造方法
JP2003171354A (ja) 光学活性アミン化合物又はその塩の製造方法
HU227730B1 (en) Process for the preparation of duloxetine and for their the intermediates
JP2000319256A (ja) ３，７−二置換インドール誘導体並びにその光学活性体の製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078087

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078087

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080917

Termination date: 20091110